Signals mentioning Fluence Pharma
- Honasa calls off ₹135 crore acquisition of 58% stake in Fluence Pharma
- Honasa Consumer's called-off ₹135 crore Fluence Pharma acquisition resurfaces from August
- Honasa Consumer’s Q1 FY27 revenue rises 27% to Rs 756 crore; profit more than doubles
- Honasa buys majority stake in Fluence Pharma, betting on health-beauty convergence
- Indian Startups Raise $1.1 Bn This Week; CRED Leads With $900 Mn Series H
- Sofina Ventures Trims Honasa Stake With ₹177 Cr Bulk Deal at ₹424/Share
- Sofina Ventures exits 1.28% of Honasa Consumer in ₹177 Cr bulk deal at ₹424/share
- Sofina Ventures trims Honasa stake by 1.28% in Rs 177 Cr bulk deal
- Sofina offloads Rs 177 Cr Honasa stake as VC exits from listed D2C brands accelerate
- Honasa buys 58% of Fluence Pharma for Rs 135 cr, launches Honasa Health to enter VMS market
- Honasa buys 58% of Fluence Pharma, launches Honasa Health to enter nutraceuticals
- Honasa slips 3% after ₹135 cr Fluence Pharma deal to enter nutraceuticals
- Honasa buys 58% of Fluence Pharma at ₹135 cr, pushes Mamaearth parent into nutraceuticals
- Honasa buys 58% of Fluence Pharma, opens nutraceuticals front beyond Mamaearth
- Honasa buys 58% of Fluence Pharma for Rs 135 cr, launches Honasa Health for nutraceuticals
- Honasa Consumer Acquires 58% Stake in Fluence Pharma, Enters Nutraceuticals
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals via Honasa Health
- Honasa Buys 58% of Fluence Pharma for Rs 135 Cr, Launches Honasa Health for Nutraceuticals
- Honasa Consumer acquires 58% of Fluence Pharma at Rs 135 cr EV, launches Honasa Health subsidiary
- Honasa Buys 58% Of Fluence Pharma, Pushes Mamaearth Into Beauty-From-Within